TogoTuberculosis profile
Population  2015 7.3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.46 (0.28–0.7) 6.4 (3.8–9.5)
Mortality (HIV+TB only) 0.2 (0.047–0.47) 2.8 (0.64–6.4)
Incidence  (includes HIV+TB) 3.8 (2.7–5.1) 52 (37–69)
Incidence (HIV+TB only) 0.82 (0.53–1.2) 11 (7.2–16)
Incidence (MDR/RR-TB)** 0.13 (0–0.28) 1.8 (0–3.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.23 (0.11–0.36) 1.2 (0.61–1.9) 1.5 (0.72–2.2)
Males 0.23 (0.14–0.32) 2.1 (1.5–2.7) 2.3 (1.7–3)
Total 0.46 (0.31–0.62) 3.3 (2.7–4) 3.8 (2.7–5.1)
TB case notifications, 2015  
Total cases notified 2 671
Total new and relapse 2 613
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status 100%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 69% (52–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.18 (0.1–0.29)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 561 21%
          - on antiretroviral therapy 511 91%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  79
(0–170)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 12% (7–19)  
% notified tested for rifampicin resistance 0% 55% 80
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 88% 2 415
Previously treated cases registered in 2014 76% 162
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 56% 16
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
40% (37–44)
TB financing, 2016  
National TB budget (US$ millions) 3.5
Funding source: 7% domestic, 46% international, 47% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data